

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_82346
Title of the Manuscript:	Statins for the treatment of liver fibrosis in chronic hepatitis-c patients
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

<https://www.journaljpri.com/index.php/JPRI/editorial-policy>

Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<p>Some grammatical changes: "Patients" is misspelled throughout – please correct</p> <p>There are MANY other spelling errors throughout. Once again, please proofread and correct.</p> <p>"Child-Puh" should be capitalized</p> <p>Results: <i>There were 73 patients in each group. Fibrosis progression occurred in 7(9.6%) patients in group-A and 23(31.5%) in group-A</i> – Please revise group labelling in this sentence</p> <p><i>In the USA alone, there are 3.5 million Hepatitis C virus-infected people</i> – wording change</p> <p><i>The exclusion criteria were the patients having decompensated liver disease or Hepatocellular carcinoma, or have liver disease due to causes other than hepatitis C and the patient already taking statin therapy.</i> – reword to make more clear</p> <p>Content revisions:</p> <p>Would like more Background in intro regarding shear-wave elastography and the grading of stages, and how it relates to disease.</p> <p>As an exclusion criteria it was stated that participants were not on statin therapy - What about other dyslipidemia agents? Where these excluded?</p> <p>What statin was used? If not disclosable, what intensity statin (moderate? High)? It says in the methodology that dose of statin was recorded. Did dosage affect amount of fibrosis in the intervention group?</p> <p>What anti-viral was used. Was it the same agent in both groups? Were they on prior anti-viral therapy?</p> <p>Were HCV viral loads compared to in both groups?</p> <p>What is defined as "efficacy" by the study investigators? It is stated but not defined. Is it absolute amount of fibrosis? Progression of fibrosis, etc?</p> <p>It is not clear what was the baseline shear-wave results on groups and the end-point after treatment.</p>	
Minor REVISION comments	<p>In the introduction – is there more information regarding the proposed mechanism of why statins help halt the progression of fibrosis? – I know this was mentioned in discussion, but some in the intro would be good to lay the framework.</p>	
Optional/General comments	<p>A good study for improving care of patients. A lot of effort went into exploring characteristics of the two groups, and matching the participants.</p> <p>There are many holes left that are unanswered as listed above, and most importantly, what is</p>	

Review Form 1.6

	the exact definition of efficacy in regards to shear wave imaging results Overall as well, the paper has many spelling, grammatical and flow errors. I listed just some above but a MAJOR rewrite has to be done, as the points do not get across well due to the wording	
--	--	--

PART 2:

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Seth Politano
Department, University & Country	Keck School of Medicine of USC, United States